Infusional floxuridine‐based therapy for patients with metastatic renal cell carcinoma

Abstract

FUDR in conjunction with IL-2 or interferon appears to produce response rates comparable to those observed with other programs utilizing BRMs and generally is well tolerated. FUDR regimens may be useful in the treatment of metastatic RCC in the outpatient community setting.

Metastatic Renal Cell Carcinoma to the Head and Neck

“… 2 Distant metastases commonly occur, with 30% to 40% of patients presenting with metastatic disease. 3 The most frequent sites, in decreasing order, are the lung (76%), regional lymph nodes (66%), bone (42%), and liver (41%). 4 Approximately 15% of patients with RCC have extracranial head and neck metastases.…”

“…Partial response rates range from 5% to 20%, with complete responses generally observed in less than 5% of patients. 3 The patient in case 2 had residual disease after the resection diagnosed by endoscopy and biopsy. He was treated with 2 months of interleukin‐2, interferon‐α, and 5‐fluorouracil.…”

“…A recent study used infusional floxuridine‐based therapy in conjunction with interleukin‐2 or interferon‐α 2b and has produced at least partial responses in 25% of patients. 3 …”

Cervical lymph node metastases from remote primary tumor sites

“…The systemic treatment of metastatic RCC includes immune modulating agents interleukin‐2 or interferon‐α along with newer treatment regimens, including sorafenib, sunitinib, and temsirolimus . Partial response rates range from 5% to 20%, with complete responses generally observed in <5% of patients . It may be used with the additional use of immune modulating agents and biotherapy should be considered as adjuvant therapy to treat residual disease after the resection, as discussed and supported by members of the multidisciplinary cancer team …”

Mohs surgery in metastatic cancer: renal cell carcinoma solitary cutaneous metastasis and visceral tumor metastases to skin treated with microscopically controlled surgical excision

“…5‐Fluorouracil has also been used concurrently with these treatments . Chemotherapeutic treatment results for cutaneous metastases of RCC are unsatisfactory, with maximal partial response rates of 5–20% reported …”